Pharmacological manipulation of nitric oxide (NO) has been suggested as a promising treatment for schizophrenia symptoms. A single infusion of sodium nitroprusside, a NO donor with short half-life, was found to improve schizophrenia symptoms. However, an increasing number of preclinical studies have demonstrated the potential beneficial effects of both NO donors and inhibitors. We investigated the potential synergistic effect of sub-effective doses of the NO donor sodium nitroprusside or the NO inhibitor 7-Nitroindazole (7NI) combined with clozapine, a standard atypical antipsychotic, on counteracting amphetamine or MK-801-induced psychosislike behaviors. The impact of sodium nitroprusside and 7NI on cAMP regulation in the prefrontal cortex and striatum was also evaluated. Confirming previous results, we found that both NO donors and inhibitors prevented amphetamine-induced effects (prepulse inhibition [PPI] disruption and hyperlocomotion). In addition, we observed a synergistic effect of sodium nitroprusside and clozapine on antagonizing the disruptive effects of amphetamine, but not MK-801, in the PPI test. The sub-effective dose of 7NI tested did not prevent amphetamine or MK-induced PPI effects when combined with clozapine. Interestingly, cAMP levels were significantly decreased in the prefrontal cortex after treatment with sodium nitroprusside. In the striatum, both sodium nitroprusside and 7NI blocked the amphetamine-induced increase of cAMP. Our data corroborate previous findings on the dopaminergic mechanisms involved in the action of sodium nitroprusside. It is likely that the differential effects of sodium nitroprusside are related to its ability to modify cAMP levels in the prefrontal cortex.
Introduction
Dopamine and glutamate are neurotransmitters classically associated with the set of schizophrenia symptoms (van Rossum, 1966; Baumeister and Francis, 2002; Goff and Coyle, 2001; Coyle, 2012; Seeman, 2013) . The oldest biological hypothesis for positive symptoms of schizophrenia is based on the exacerbation of mesolimbic dopamine neurotransmission (Stevens, 1973; Kapur et al., 2005) . Dopamine hypothesis is supported by the correlation between clinically effective doses of antipsychotics and their potency to antagonize dopamine D2 receptors. The anatomical specificity of this hypothesis was corroborated by molecular imaging studies of dopamine function (Creese et al., 1976; Howes and Kapur, 2014) . Furthermore, it has been proposed that a deficit in dopamine transmission at D1 receptors in the prefrontal cortex might be involved in the cognitive impairments and negative symptoms of schizophrenia (Davis et al., 1991; Howes and Kapur, 2009) .
The hypofunction of N-methyl-D-aspartate (NMDA) glutamate receptor was also pointed out to explain the various symptoms of schizophrenia (Laruelle, 2014; Moghaddam and Javitt, 2012) . Both cortical dopamine deficit and subcortical dopamine hyperactivity characterized in schizophrenia might be related to a persistent alteration in NMDA transmission (Laruelle, 2014) . Interestingly, these dopaminergic changes could increase the severity of glutamate hypofunction, thus both glutamate and dopamine imbalance seems to strengthen one another (Laruelle, 2014; Centonze et al., 2001) .
In addition to this complex scenario, the gaseous neurotransmitter nitric oxide (NO) has been implicated in the pathogenesis of schizophrenia (Bernstein et al., 2011) . However, the effect of NO abnormality in schizophrenia is still under debate, since both high and low levels of NO metabolites have been linked to this pathology (Bernstein et al., 2011) . The activation of NMDA receptor leading to calcium influx stimulates neuronal NO synthase (nNOS). The blockade of NMDA receptors by drugs such as ketamine and phencyclidine produces schizophrenia-like symptoms and reduces NO production (Oliveira et al., 2011) . Importantly, NO is involved in uptake and release processes of dopamine and glutamate, in the former due to its ability to activate extrasynaptic receptors (Kiss and Vizi, 2001; Kiss et al., 2004; Mitkovski et al., 2012; Nasyrova et al., 2015) . On the other hand, dopamine modulates nNOS activity in the dorsal striatum via both facilitatory (D1 receptor activation) and inhibitory (D2 receptor activation) signaling (Hoque et al., 2010) .
From an anatomical point of view, the striatum is the local of convergence of glutamate cortical afferents and dopaminergic projections, where NO might also mediate the interaction between these neurotransmitters (Hoque et al., 2010) . Several evidence corroborates the interaction between dopamine, glutamate and NO (Kiss and Vizi, 2001; Vizi et al., 2004; Mitkovski et al., 2012; Snyder and Ferris, 2000) , and this knowledge provides new possibilities for the comprehension and treatment of schizophrenia symptoms.
The current available treatment for schizophrenia symptoms consists of typical (ex. haloperidol and chlorpromazine) and atypical antipsychotics (ex. clozapine, olanzapine, quetiapine and risperidone). However, considering the large number of schizophrenia patients who respond poorly to the usual pharmacological treatments, there is ample interest in improving pharmacological strategies to treat residual schizophrenia symptoms. The atypical antipsychotic clozapine is the only drug treatment currently licensed for patients with treatment-resistant schizophrenia (Taylor et al., 2010) . Typical and atypical antipsychotics block dopamine D2 receptors; however the differences between typical and atypical antipsychotics may arise from some non-D2-receptor activity (for review Kapur and Remington, 2001) .
Interestingly, preclinical studies have demonstrated beneficial therapeutic effects of both NO donors and inhibitors (for review, Pitsikas, 2015 Pitsikas, , 2016 . In addition, a significant clinical improvement in acute schizophrenia symptoms was observed after the intravenous administration of the NO donor sodium nitroprusside as an adjunct treatment to patients that were receiving atypical antipsychotics (Hallak et al., 2013) .
Although there is no appropriate animal model of schizophrenia, prepulse inhibition (PPI), a behavioral paradigm used to assess information-processing mechanisms, is used frequently in pharmacological studies to predict the antipsychotic-like effects of new compounds . A deficiency in normal central inhibitory processes is observed in several major psychiatric disorders involving corticostriato-thalamic circuit unsettling Swerdlow et al., 2016) , including schizophrenia . Thus, PPI is regulated by disorder-relevant forebrain circuitry ), serving as a robust measure of neurobiological processes (Swerdlow et al., 2017) . In rodents, PPI is pharmacologically disrupted by dopamine agonists and NMDA antagonists (Salum et al., 2006; Issy et al., 2009; Klamer et al., 2001) . Experimental PPI has predictive validity since its impairment is prevented by typical and atypical antipsychotics (for review Meltzer, 2013) .
We previously described the ability of both NO donors and inhibitors to prevent the disruptive effect of amphetamine or its analogue methylphenidate in the PPI test (Issy et al., 2009 Salum et al., 2006 Salum et al., , 2011 . Our previous results support the hypothesis that prevention of PPI impairment through NO inhibition encompasses a decrease in cGMP (Issy et al., 2009 ). Despite the fact that NO seems to be critical to the cGMP pathway, since it functions as the primary activator of soluble guanylate cyclase (sGC; Derbyshire and Marletta, 2012) , the effect of NO donors on counteracting amphetamine-induced PPI deficit does not appear to be related to an increase in cGMP . Interestingly, cAMP-mediated effects of NO have also been described (Karatinos et al., 1995; Klamer et al., 2005) .
To address to the paradoxical effects of NO donors and inhibitors on experimental psychiatric models, we investigated a potential synergistic effect of the NO donor sodium nitroprusside or neuronal NOS inhibitor 7-Nitroindazole (7NI) and the atypical antipsychotic clozapine on counteracting the psychotomimetic effects of either amphetamine or the glutamate antagonist, MK-801. Despite the recognized ability of nNOS inhibitors to counteract NMDA antagonist-induced PPI disruption (Johansson et al., 1997; Klamer et al., 2001; Klamer et al., 2004) , it remains to be determined if sodium nitroprusside presents similar effects on this model. Since the molecular mechanism shared by NO donors and inhibitors is not likely to entirely depend on the sGC/cGMP pathway, we conducted an ex vivo analysis to explore the impact of these NO compounds on cAMP levels in the striatum and prefrontal cortex, two critical regions involved in antipsychotic-like effects.
Materials and methods

Subjects
Male Swiss mice (8-12 weeks; 25-35 g; from University of São Paulo, Campus Ribeirão Preto, Brazil; n = 235) were used. Prior to the experiments, animals were housed in groups of five and maintained at 23 ( ± 1)°C with a 12-h/12-h light/dark cycle (lights on at 6:00 a.m.). Food and drinking water were available ad libitum. The tests were performed during the light phase with a minimum interval of four days for drug washout. The experimental protocol followed the Ethical Principles in Animal Research delineated by the guidelines for the care and use of mammals in Neuroscience and Behavioral Research and was approved by the Ethics Committee on the Use of Experimental Animals of the University of São Paulo, Ribeirão Preto.
Drugs
All solutions were freshly prepared on the day of testing. Sodium nitroprusside (Sigma), d-amphetamine (Sigma), MK-801 (Sigma), haloperidol (haldol, Janssen Cilag®) and SKF38393 (Tocris) were dissolved in 0.9% sterile saline. Clozapine (Sigma) was dissolved in sterile saline/acetic acid 0.5% (v/v). 7-Nitroindazole (7NI; Sigma) was dissolved in PEG (polyethylene glycol; 50%). Systemic administration was made in a volume of 10 ml/kg intraperitoneally.
Prepulse inhibition
The testing was conducted simultaneously in two identical startle response systems (Med Associates, Inc., USA) as previously reported (Issy et al., 20014a) . The pulse (pulse alone, P) was a burst of white noise of 105 dB with a rise/decay of 5 ms and duration of 20 ms. Prepulses were used in an intensity of 73, 77, or 81 dB, frequency of 7 kHz, and a duration of 10 ms. The interval between the onset of the prepulse and the pulse was 100 ms, and the inter-stimuli interval was 30 s. The 64 trials conducted were divided into four different categories: (1) pulse alone, (2) prepulse alone, (3) prepulse and pulse, and (4) no stimulus. The level of PPI was determined by expressing the prepulse plus pulse startle amplitude as a percentage of the pulse-alone startle amplitude according to the following formula: % PPI = [100 × (startle mean to pulse alone trials -startle mean to prepulse-pulse trials)/startle mean to pulse alone trials]. The platform calibration was performed by adjusting the gain on the load cell amplifier to 150 arbitrary units (AU) at a standard weight of 40 g. The limits of the load cell were − 2047 to +2047 AU.
Open field test
Locomotor activity was measured during 10 min in a circular arena (40 cm diameter surrounded by 49-cm-high walls). Behavior in the arena was recorded by a video camera mounted on the ceiling and relayed to a videocassette recorder coupled with a computer equipped by a video tracking, motion analysis and behavior recognition system (ANY-maze 4.9, Stoelting USA) for data acquisition. The total distance traveled was registered in meters.
cAMP assay
The right and left hemispheres from prefrontal cortex and striatum samples were pooled; cut into 2mm 2 , 2 pieces in MEM buffered with 20 mM HEPES (pH 7.4) in oxygenated medium followed by pharmacological stimulus. Drugs that alter nitrergic neurotransmission and the typical and atypical antipsychotics were added to the oxygenated tissue. Five minutes later, saline or amphetamine was added. Control group (haloperidol, clozapine and SKF 38393) was tested only with saline. Five minutes after the second stimulation the tissues underwent the inhibition of phosphodiesterase 4 (rolipram; 500 μM) were brought to 37°C bath and maintained for 1 h. The reaction was stopped by adding 10% trichloroacetic acid (final concentration). The cAMP was purified and assayed by previously described methods (Matsuzawa and Nirenberg, 1975; de Mello et al., 1982) and then normalized to protein content assayed by Lowry method (Lowry et al., 1951) .
Ex vivo treatment
Vehicle (10 μl); sodium nitroprusside (0.3 mM or 1 mM) or 7NI (0.3 mM or 1 mM) associated with saline or amphetamine (10 μM; Herdon et al., 1985) . As positive controls, dopaminergic D1 agonist SKF 38393 (100 μM; Conroy et al., 2015) and typical and atypical antipsychotics, haloperidol and clozapine (10 μM; Fontanilla et al., 2009 , Kang et al., 2004 , Masri et al., 2008 were used.
Experimental design
For evaluation of synergistic effects in amphetamine or MK-801 models, we used independent groups to avoid the psychotomimetic treatment recurrence. In other conditions, animals were used to test both control and challenge effects of amphetamine or MK-801 treatment. In all cases, the animals were re-subjected to the PPI test at intervals of 3-4 days to ensure drug washout. The atypical antipsychotic clozapine was administered 50 min before PPI. Sodium nitroprusside and 7NI were administered 30 min before PPI. Amphetamine or MK801 were administered 20 min after sodium nitroprusside or 7NI and 10 min before PPI.
2.6.1. Experiment 1 2.6.1.1. The ability of NO compounds to prevent amphetamine-induced effects. Our aim was to replicate the ability of the NO donor sodium nitroprusside and the nNOS inhibitor 7NI to prevent the effects of amphetamine on the PPI paradigm using different prepulse intensities and amphetamine dose, from those previously used (Issy et al. 2014a (Issy et al. , 2014b . The subjects received saline (10 ml/kg), sodium nitroprusside (2.5 or 3.5 mg/kg) or 7NI (1 or 3 mg/kg) alone or preceding amphetamine (5 mg/kg) and were subsequently subjected to the PPI test (n = 30). In an independent experimental group, subjects treated with sodium nitroprusside 2.5 mg/kg or 7NI 3 mg/kg were tested in the open field (n = 44).
2.6.2. Experiment 2 2.6.2.1. Synergistic effect of sodium nitroprusside or 7NI and clozapine association on preventing amphetamine-induced effects. To evaluate the synergistic effect of clozapine and sodium nitroprusside or 7NI association, subjects received saline (10 ml/kg), clozapine (1 mg/kg), sodium nitroprusside (0.1, 0.3 or 1 mg/kg) or 7NI (10 mg/kg) alone or preceding amphetamine (5 mg/kg) and were subsequently subjected to the PPI and open field tests (n = 70). These sub-effective doses of NO compounds were selected based on previous studies conducted in our laboratory (Issy et al., 2009 .
2.6.3. Experiment 3 2.6.3.1. The ability of sodium nitroprusside to prevent MK-801-induced effects. Despite the recognized ability of NOS inhibitors to counteract NMDA antagonist-induced PPI disruption (Johansson et al., 1997; Klamer et al., 2001; Klamer et al., 2004) , whether sodium nitroprusside has similar effects on NMDA-based PPI disruption is unknown. Based on the above information, we investigated whether the effects of sodium nitroprusside extend to the NMDA antagonist model.
Subjects received saline (10 ml/kg) or sodium nitroprusside (2.5, 3.5 or 4 mg/kg) alone or preceding MK-801 (0.5 mg/kg, n = 33). The sodium nitroprusside doses were based on a previous study . These individuals were successively subjected to PPI and open field tests, with the exception of individuals who received sodium nitroprusside mg/kg (with and without MK-801). Previous studies already reported the ability of either neuronal selective and non-selective NO synthase inhibitors (NPLA and L-NAME) to counteract phencyclidine-induced hyperlocomotion in mice and rats, respectively (Klamer et al., 2004; Johansson et al., 1997) .
The potential synergistic interaction between sodium nitroprusside (1 mg/kg) or 7NI (1 mg/kg) and clozapine (1 mg/kg) on the MK-801 model was also evaluated in the PPI test (n = 18). Sodium nitroprusside and clozapine doses were based on experiment 2. In contrast to the amphetamine model, the dose of 1 mg/kg of 7NI was not found to modify the MK801 effect.
The standard atypical antipsychotic clozapine (2.5 mg/kg) was tested preceding MK-801-induced PPI disruption as a positive control.
2.6.4. Experiment 4 2.6.4.1. cAMP level evaluation in the prefrontal cortex and striatum. Mice were subjected to cervical dislocation, and brains were rapidly dissected and kept on a cold physiological saline solution. The regions of interest (prefrontal cortex and striatum) were dissected with a specific matrix to perform neurochemical experiments (n = 42). Experimental groups were designed incubating tissue with: saline (10 μl); amphetamine (10 μM); sodium nitroprusside alone (0.3 mM or 1 mM) or associated with amphetamine (10 μM); and 7NI alone (0.3 mM or 1 mM) or associated with amphetamine (10 μM). As positive controls, the tissues were incubated with SKF 38393 (100 μM); haloperidol (10 μM) or clozapine (10 μM).
Statistical analysis
The PPI data were analyzed by two-way ANOVA using the first (saline, sodium nitroprusside, 7NI, clozapine, clozapine plus sodium nitroprusside or clozapine plus 7NI) and the second (amphetamine or MK-801) treatments as main factors. The cAMP data were analyzed by two-way ANOVA using the first (saline, sodium nitroprusside or 7NI) and the second (saline or amphetamine) treatments as main factors. In cases of significant interactions between factors, specific one-way ANOVAs were performed. The positive controls (saline, SKF, clozapine or haloperidol) were analyzed by one-way ANOVA. Duncan's test was used for post hoc analysis. All data are expressed as the mean ± the standard error of mean (SEM). For all experiments, the level of significance was set at p < 0.05.
Results
Experiment 1:
The ability of NO compounds to prevent amphetamineinduced effects Our first step was to confirm the beneficial effects of NO donor sodium nitroprusside and nNOS inhibitor 7NI in amphetamine-induced PPI disruption in different prepulse intensities, here evaluated at 73, 77 and 81 dB. We previously described the effect of sodium nitroprusside and 7NI at 80, 85 and 90 dB prepulse intensities .
The analyses of variance revealed a significant effect of the prepulse intensity [F 2,90 = 7. 055, p = 0.001] and treatment [F 9,45 = 9.850, p = 0.000] but not an interaction between the prepulse intensity and the treatment [F 18,90 = 0.721, p = 0.781]. Since there was not an interaction between prepulse intensity and treatment, PPI was collapsed across all prepulse intensities (Fig. 1A) . We confirmed our previous results, since the post hoc analysis revealed a disruptive effect of amphetamine at all prepulse intensities. Both sodium nitroprusside (2.5 mg/kg) and 7NI (1 and 3 mg/kg) treatment significantly counteracted the amphetamine effect at prepulse intensity of 81 dB (p < 0.05).
Concerning locomotion evaluation, the one way analysis revealed that amphetamine induced a significant increase in mice locomotion activity (F 5,43 = 20.479, p = 0.000; Fig. 1B ). Amphetamine-induced hyperlocomotion was significantly attenuated by either sodium nitroprusside (2.5 mg/kg) or 7NI (3 mg/kg), as revealed by Duncan post hoc analysis (p < 0.05).
3.2. Experiment 2: Synergistic effect of sodium nitroprusside or 7NI and clozapine association on preventing amphetamine-induced effects Next, we analyzed if sub-effective doses of sodium nitroprusside and 7NI associated to a sub-effective dose of the atypical antipsychotic clozapine would be effective in preventing PPI disruption induced by amphetamine.
Our data revealed a synergistic effect of sodium nitroprusside and clozapine association. The analyses of variance revealed a significant effect of the prepulse intensity [ In general, the combination of clozapine and sodium nitroprusside increased PPI performance in subjects injected with amphetamine, achieving a significant effect at a dose of 1 mg/kg in the prepulse intensities of 77 dB [F 10,79 Fig. 2A) . At a prepulse intensity of 81 dB, sodium nitroprusside at 1 mg/kg, individually, showed a performance similar to clozapine plus sodium nitroprusside at the same dose (p < 0.05). Combined doses of 7NI and clozapine did not modify amphetamine effect (p > 0.05). Subthreshold doses of sodium nitroprusside, 7NI or clozapine, individually, did not counteract amphetamine-induced PPI disruption (p > 0.05; post hoc Duncan analysis).
The hyperlocomotion induced by amphetamine (F 10,79 = 3.760, p = 0.000; one-way ANOVA, post hoc Duncan) was not prevented by sub-effective doses of sodium nitroprusside and clozapine combination (p > 0.05; Fig. 2B ). There is no significant difference between saline and 7NI (10 mg/kg) treated groups (p < 0.05; post hoc Duncan analysis; Fig. 2B ).
Experiment 3: The ability of sodium nitroprusside to prevent MK-801-induced effects
We also evaluated the ability of NO modulators sodium nitroprusside and 7NI to inhibit PPI disruption induced by the NMDA antagonist MK-801.
The analysis of variance revealed a significant effect of the prepulse intensity [F 2,100 = 21. 748, p = 0.000] and treatment [F 7,50 = 10.767, p = 0.000] but not an interaction between the prepulse intensity and treatment [F 14,100 = 1.519, p = 0.118] . Surprisingly, the doses of sodium nitroprusside tested individually in our work (2.5, 3.5 or 4 mg/kg) did not prevent MK-801-induced PPI disruption ( Fig. 3A ; One Way ANOVA, post hoc Duncan; p > 0.05).
In addition, we did not observe a synergistic interaction between sub-effective doses of sodium nitroprusside (1 mg/kg) or 7NI (1 mg/kg) combined with clozapine in the MK-801-induced PPI disruption ( Fig. 3B; p > 0.05) . The analyses of variance revealed a significant Fig. 1 . Effects of sodium nitroprusside in the amphetamine-induced PPI disruption and hyperlocomotion. A. The disruptive effect of amphetamine (5 mg/kg) in the PPI test was revealed at all prepulse intensities. Sodium nitroprusside (NPS; 2.5 mg/kg) and 7NI (1 and 3 mg/kg) significantly counteract the amphetamine effect at prepulse intensity of 81 dB. Saline (n = 6); NPS 2.5 (n = 5); NPS 3.5 (n = 5); 7NI 1 (n = 6); 7NI 3 (n = 8); amphetamine (n = 5); NPS 2.5 + amphetamine (n = 5); NPS 3.5 + amphetamine (n = 6); 7NI 1 + amphetamine (n = 6); 7NI 3 + amphetamine (n = 8); total (n = 30; animals were resubmitted to PPI as its own control). B. Amphetamine (5 mg/kg) significantly increases mice locomotion. Sodium nitroprusside (2.5 mg/kg) and 7NI (3 mg/ kg) significantly attenuated amphetamine-induced hyperlocomotion. n = 7-8 per treatment (total, n = 44).* #+ post hoc Duncan's test; *p < 0.05 compared with saline; # p < 0.05 compared with amphetamine; +p < 0.10 compared with saline.
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As observed in the open field test, MK-801 induced hyperlocomotion (p < 0.05 vs. control), but sodium nitroprusside (3.5 mg/kg) preceding MK-801 prevented this effect (p < 0.05 vs. sal-MK-801). However, it appears that sodium nitroprusside decreases locomotor activity on its own (p < 0.05 vs. control), rather than blocking the effect of MK-801 ( Fig. 4D ; one-way ANOVA, post hoc Duncan, F 5,44 = 4.930, p = 0.001).
Experiment 4: cAMP level evaluation in the prefrontal cortex and striatum
To observe whether NO modulators could act in an alternative mechanism than the strict change of NO signaling (sGC/cGMP), our next step was to measure cAMP levels in the prefrontal cortex and striatum of amphetamine-treated mice.
In the prefrontal cortex, amphetamine did not induce any significant alteration in cAMP levels. Similarly, the NO inhibitor (7NI) did not induce any significant alteration in the cAMP levels in the prefrontal cortex (p > 0.05). However, the NO donor sodium nitroprusside significantly decreased cAMP levels in this region (p < 0.05). Similar results were found with the NO donor and amphetamine combination (p < 0.05). The analysis of variance (two-way ANOVA) revealed a main effect of treatment 1 (saline or sodium nitroprusside or 7NI; 0.3 mM or 1 mM; F 4,59 = 23.052, p = 0.00) but not treatment 2 (saline or amphetamine; F 1,59 = 3.194, p = 0.080); moreover, there was no interaction between treatment 1 and 2 (F 4,59 = 1.252, p = 0.301; Fig. 4A ).
In the striatum, amphetamine significantly increased cAMP levels (p < 0.05). Both the NO donor sodium nitroprusside and inhibitor 7NI counteracted the effect of amphetamine in the striatum (p < 0.05). The analyses of variance revealed a main effect of treatment 1 (saline or sodium nitroprusside or 7NI; 0.3 mM or 1 mM; F 4,60 = 29.157, p = 0.00) and treatment 2 (saline or amphetamine, F 1,60 = 11.726, p = 0.001) and an interaction between treatments 1 and 2 (F 4,60 = 18.005, p = 0.00; Fig. 4C ). Additionally, sodium nitroprusside at a concentration of 0.3 mM combined with amphetamine significantly decreased cAMP levels compared to the saline group (p < 0.05; post hoc Duncan analysis).
The positive control, D1 dopaminergic agonist SKF, induced a significant increase of cAMP in both the prefrontal cortex (F 3,21 = 17.887, p = 0.00; Fig. 4B ) and the striatum (F 3,23 = 27.199, p = 0.00; Fig. 4D ). Clozapine also reduced cAMP levels compared to the haloperidol group in the striatum (p < 0.05).
Discussion
The connection between NO and schizophrenia has many dimensions. Several anatomical and functional evidence corroborates the interaction between dopamine, glutamate and NO (Kiss and Vizi, 2001; Kiss et al., 2004; Mitkovski et al., 2012; Snyder and Ferris, 2000) . Furthermore, NOS gene polymorphisms, and the role of NO in reactive oxidative stress may contribute to the schizophrenia pathophysiology (for review Nasyrova et al., 2015) .
Recently, pharmacological strategies that manipulate NO system have been investigated as promising treatments for schizophrenia symptoms (Hallak et al., 2013; Maia-de-Oliveira et al., 2015a; Maia-deOliveira et al., 2016; Pitsikas, 2015 Pitsikas, , 2016 . The paradoxical ability of either NO donors or inhibitors to prevent amphetamine-induced PPI effects was confirmed in this study, using prepulse intensities different from those we previously used . Similar results were found regarding amphetamine-induced hyperlocomotion, being original for the effect of the NO donor.
Interestingly, in the current study we observed a synergistic effect of sub-effective doses of combined sodium nitroprusside and clozapine A.C. Issy et al. Progress in Neuropsychopharmacology & Biological Psychiatry 86 (2018) 353-362 treatment on preventing amphetamine-induced PPI disruption. This finding seems relevant since synergistic drug interaction may be an effective strategy to treat complex disease symptoms, such as those occurring in schizophrenia, with few undesirable side effects. We could speculate that combined sodium nitroprusside and clozapine treatment might increase the clozapine ability to improve treatment-resistant schizophrenia symptoms. On the other hand, we did not observe a synergistic interaction between sub-effective doses of 7NI (10 mg/kg) and clozapine (1 mg/kg) on PPI. A bell-shaped curve was likely reached by both sodium nitroprusside (3.5 mg/kg; experiment 1) and 7NI (10 mg/ kg; experiment 2), since, these compounds at higher concentrations had no effect on amphetamine-induced PPI disruption. This biphasic pattern is commonly observed with NO compounds (Inan et al., 2004) , and different to standard sigmoidal curves, bell-shaped concentration-response curves suggest more complex biological effects, such as multiple-binding targets (Owen et al., 2014) . There was no synergistic effect observed between the NO donor or inhibitor and the atypical antipsychotic clozapine in preventing amphetamine-induced hyperlocomotion. The reason for this finding is unknown. More research on the neural substrate involved in PPI disruption and hyperlocomotion induced by amphetamine could provide important information about this finding. The nucleus accumbens is a critical region involved in the hyperlocomotion induced by amphetamine-like drugs (Iversen, 1987) , which is prevented by current antipsychotics, and is proposed to mediate the antipsychotic effects against the positive symptoms of schizophrenia (Seeman, 2002) , supporting face and predictive criteria for this model. On the other hand, PPI is clearly dependent on a broad range of forebrain structures, including the nucleus accumbens . Interestingly, there is an important connection between the nucleus accumbens and several corticolimbic structures, such as the amygdala, hippocampus and prefrontal cortex (Shirayama and Chaki, 2006) . Our data suggest that the synergic interaction observed to prevent amphetamine-induced PPI impairment may not be exclusively dependent upon the mobilization of the nucleus accumbens.
Unexpectedly, the range doses of sodium nitroprusside tested here, including the effective dose for counteracting the effect of amphetamine, did not modify MK-801-induced PPI disruption. Our experimental design (evaluated doses, prepulse intensities and interval of drug administration) failed to reveal beneficial effects of sodium nitroprusside on MK-801-induced PPI disruption. We had previously tested a different NO donor (sodium trioxdinitrate, 3 and 10 mg/kg; i.p.) against MK-80-induced PPI effects, and we failed to observe any such effects (data not published). In addition, the synergistic interaction between an NO donor or inhibitor and the atypical antipsychotic was not found to be effective against MK-801-induced PPI disruption. We also found that the effective dose of 7NI (1 mg/kg) against amphetamine-induced PPI disruption did not prevent MK801 effects (experiment 2). The reason for this failure is unclear; however, clozapine exerted its expected effect as a positive control.
The ability of NOS inhibitors to prevent attentional deficits related to glutamatergic hypofunction, including those measured through PPI, is corroborated by several works (Johansson et al., 1997; Klamer et al., 2001; Klamer et al., 2004; Pålsson et al., 2007) . It has been previously described that the disruption of PPI induced by phencyclidine is Fig. 3 . Effects of sodium nitroprusside pretreatment in the MK-induced PPI disruption and hyperlocomotion. A. The disruptive effect of MK801 (0.5 mg/kg) in the PPI test was revealed at all prepulse intensities. Sodium nitroprusside (2.5, 3.5 or 4 mg/kg) did not counteract the MK-801-induced PPI disruption (n = 33; n = 6-8 per treatment). B. Sodium nitroprusside (1 mg/kg) or 7NI (1 mg/kg) and clozapine (1 mg/kg) association did not counteract the MK-801 disruptive effect in the PPI (n = 18; n = 9 per treatment). C. Clozapine treatment prevented MK801-induced PPI disruption in all prepulse intensities. D. Sodium nitroprusside did not prevent MK-801-induced hyperlocomotion. *# post hoc Duncan's test; *p < 0.05 compared with saline; # p < 0.05 compared with MK-801.
A.C. Issy et al. Progress in Neuropsychopharmacology & Biological Psychiatry 86 (2018) 353-362 modulated by the activation of NO/sGC/cGMP, given that this effect was attenuated by both NO and sGC inhibitors (Fejgin et al., 2008) . Interestingly, phencyclidine treatment increased NO levels in the prefrontal cortex and ventral hippocampus, as reported by Pålsson et al. (2010) . In this context, if the disruptive effect of MK-801 is mediated by NO increase, similar to phencyclidine effect, it seems reasonable the inability of sodium nitroprusside to prevent MK801-induced PPI disruption. However, previous studies have indicated that sodium nitroprusside prevents hyperlocomotion induced by NMDA antagonists (BujasBobanovic et al., 2000; Kandratavicius et al., 2015; Maia-de-Oliveira et al., 2015b) and attenuates recognition memory deficits and social withdrawal produced by ketamine in rats (Trevlopoulou et al., 2016) . In addition, the NO donor molsidomine attenuated stereotypy and deficits in a recognition memory test, both induced by MK-801, but failed to antagonize MK801-induced hyperlocomotion in rats (Pitsikas et al., 2006) . In mice, deficit in spatial working memory induced by MK-801 is inhibited by the increase of NO thought SNAP (Yamada et al., 1996) . Recently, Hurtubise et al. (2017) revealed sodium nitroprusside was unable to block the deleterious effects of acute MK-801 in working memory performance on the TUNL task. These discrepant results corroborate the critical pharmacology of NO donors.
The efficacy of NO donors to improve NMDA antagonists-dependent attentional deficits is still unclear. As evidence of this complex scenario, only the organic nitrates and sodium nitroprusside have long been used clinically, despite enormous potential of NO, particularly in the cardiovascular medicine (Miller and Megson, 2007) , which highlights the difficulty to handle NO pharmacology. It is noteworthy that NO donors belong to different chemical classes, with different pharmacokinetic and pharmacodynamic profiles (Miller and Megson, 2007) . Finally, the differences regarding alternative mechanisms of action of ketamine, phencyclidine and MK-801 must be considered.
Similarly, treatment-responsive and treatment-refractory schizophrenia point to fundamental differences in the pathophysiology of each schizophrenia profile (Howes and Kapur, 2014) . Clinical findings on sodium nitroprusside have included its beneficial effects against the cognitive deficit of schizophrenia patients (Maia-de-Oliveira et al., 2015a) . Nonetheless, these results were called into question when research suggested that the beneficial action of sodium nitroprusside could depend on factors such as a short schizophrenia history or acute exacerbation of symptoms (Stone et al., 2016) .
A current puzzle is the fact that sodium nitroprusside and 7NI, two compounds with opposite pharmacological actions, have similar effects on PPI (Issy et al., 2009 , 2014 . This phenomenon is not limited to information-processing mechanisms but seems to be related to other dopamine-modulated effects. This dichotomy is also observed in the model of L-DOPA induced dyskinesia (Padovan-Neto et al., 2011; Bortolanza et al., 2016; Solís et al., 2015) , and on memory deficits induced by apomorphine, as observed in the novel object recognition test that represents a type of memory impaired in schizophrenic patients (Gourgiotis et al., 2012) . Since all dopamine receptors are either positively or negatively coupled to cAMP, this cyclic nucleotide may be the molecular mechanism common to NO donors and inhibitors. As mentioned, one pharmacological property common to all currently available antipsychotic agents is their ability to block D2 dopaminergic receptor (Kapur and Remington, 2001 ), which could lead to an increase in cAMP levels (Strick et al., 2010) . The localization of phosphodiesterases is the major regulator of the local concentration of cAMP or cGMP (Bender and Beavo, 2006) . We previously reported the ability of rolipram, a phosphodiesterase 4 inhibitor that decreases cAMP metabolism, to prevent amphetamine-induced PPI disruption . Other works have already shown positive results with rolipram in preclinical studies (Siuciak, 2008; Kanes et al., 2007; Maxwell et al., 2004) . In fact, an antipsychotic-like effect in rodents has also been obtained by blocking the phosphodiesterase 10A-mediated hydrolysis of cAMP and/or cGMP (Li et al., 2016; Siuciak, 2008; Grauer et al., 2009) . Undoubtedly, the pharmacological effects of systemically injected phosphodiesterase inhibitors are dependent of the phosphodiesterases widespread in the brain. Phosphodiesterases are regulated, among other mechanisms, by the allosteric binding of cGMP or cAMP. cGMP is a low-efficacy substrate for phosphodiesterase 3 (able to hydrolyze both cAMP and cGMP), and the binding of cGMP to the catalytic site of phosphodiesterase 3 leads to the inhibition of cAMP hydrolysis, potentially raising cAMP levels (Bender and Beavo, 2006) .
In contrast, in an ex vivo preparation, we observed a decrease in cAMP either in the prefrontal cortex or the striatum (without significant effect), induced by sodium nitroprusside. A similar effect was observed Fig. 4 . Effect of NO donor or inhibitor on the cAMP concentration in the prefrontal cortex and striatum of mice (n = 42, n = 5-6 per treatment). Incubation of the tissue with amphetamine resulted in a significant increase in the concentration of cAMP in the striatum. The NO donor (sodium nitroprusside, NPS; 0.3 mM or 1 mM) per se decreased cAMP concentration in the prefrontal cortex and striatum. NPS blocked amphetamine effects on prefrontal cortex and striatum. NO inhibitor (7NI; 0.3 mM or 1 mM) did not modify per se cAMP levels in prefrontal cortex or striatum. Amphetamine effect in the striatum was blocked incubating the tissue with 7NI. The results of saline group were repeated on the two graphs in each region. *p < 0.05 compared to the sal-sal group. + p < 0.05 compared to the amphetamine group. # p < 0.05 compared to haloperidol group. One way ANOVA; post hoc Duncan. The data represent the mean ± SEM.
A.C. Issy et al. Progress in Neuropsychopharmacology & Biological Psychiatry 86 (2018) 353-362 with clozapine, which also significantly decreased cAMP levels in the striatum when compared to the saline group. In both the prefrontal cortex and striatum, 7NI did not modify cAMP on its own. The cAMP/ PKA cascade is critical for D1-like response . The increase in cAMP induced by amphetamine appears to be related to a predominant activation of striatal D1 receptors, since very similar results were found with the D1 agonist SKF in both prefrontal cortex and striatum. However, the activation of adenosine A 2A receptors present in medium spiny neurons that express D2 receptors (indirect pathway) also increases cAMP levels (Polito et al., 2013) . Here, it is important to notice that the whole striatum was considered in the analysis, without distinction between dorsal and ventral portions. Despite the interesting effects observed regarding cAMP production in this study, in a preliminary study, both sodium nitroprusside and SIN-1, another NO donor, failed to reverse the effects of amphetamine when microinjected into the prefrontal cortex (data not shown). These results suggest that even if cAMP levels in the prefrontal cortex account for the effects of systemically injected NO donors, the participation of other structures that lead to the behavioral response alteration cannot be excluded. cAMP is a second messenger derivative of adenosine triphosphate (ATP) used for intracellular signal transduction in different systems, including the CNS. The canonical activation of dopamine pathway converges into changes of intracellular cAMP levels, directly affected by several antipsychotic drugs used to treat schizophrenia symptoms. In fact, the catalytic domain of guanylyl cyclase is analogous to that of adenylyl cyclase, to the extent that switching three amino acids converts NO-activated guanylyl cyclase into NO-activated adenylyl cyclase (Sunahara et al., 1998) . In this context, it is possible that NO modulators would influence adenylyl cyclase-dependent cAMP production.
Despite the fact that our previous in vivo data did not reveal a role of cGMP in the action of sodium nitroprusside, Polito et al. (2013) previously demonstrated NO/cGMP signaling reduces cAMP signals in the dorsal striatum, acting on both striatonigral and striatopallidal medium spiny neurons. This effect depends upon the activation of phosphodiesterase 2, which has dual cAMP and cGMP hydrolase activity (Martins et al., 1982) . In the absence of cGMP, the activity of phosphodiesterase 2 is low. However, the binding of sub-micromolar cGMP to the regulatory GAF-B domain results in a 5-fold increase in the rate of cAMP hydrolysis (Martins et al., 1982; Martinez et al., 2002) . Nonetheless, this mechanism does not fully explain the effect of the NO inhibitor. Previously, Klamer et al. (2005) demonstrated that a systemic or intra-hippocampal infusion of phencyclidine induced both PPI disruption and a significant increase in cAMP in the ventral hippocampus. The NO inhibitor L-NAME (N G -nitro-L-arginine methyl ester) blocked both cAMP increase and PPI impairment (Klamer et al., 2005) . Nonetheless, the effect of NO compounds on cGMP pathway cannot be ignored since the main effector of NO signaling is cGMP (Karatinos et al., 1995) , even if NO, to a lesser extent, may act through cAMP formation by adenylyl cyclase and protein nitrosylation (Fejgin et al., 2008) .
In the striatum, sodium nitroprusside seems to antagonize the effect of amphetamine similar to 7NI, and both compounds prevent amphetamine-induced behavioral effects. Whether the ability of these compounds to prevent an increase in cAMP is necessary for their antipsychotic-like effects is a hypothesis that warrants further research. If so, cAMP may represent the molecular pathway shared by stimulation or inhibition of NO signaling in the striatum. However, since the prefrontal cortex influences the striatal dopaminergic system, sodium nitroprusside per se may have an important role in dopamine regulation. Thus, dopamine system may be sensitive to NO through different ways.
Conclusion
Together, our results highlight the complexity of NO compounds effects. Our data supports the hypothesis that dopaminergic mechanisms are involved in the action of sodium nitroprusside. In this way, additive effects would be exhibited with sodium nitroprusside combined with an antipsychotic, which may be a useful pharmacological strategy. Sodium nitroprusside and 7NI appear to have similar effects in normalizing the impact of dopamine on cAMP concentration in the striatum, but the differential effect of sodium nitroprusside could be related to its action on the prefrontal cortex, even in an undirected manner. In conclusion, this work corroborates the antipsychotic-like effect of sodium nitroprusside and its potential as an adjunctive drug.
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